Detalhe da pesquisa
1.
Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy.
Nature;
606(7915): 797-803, 2022 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35705814
2.
Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer.
Cancer;
130(7): 1061-1071, 2024 04 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38009662
3.
Detection of Residual Peritoneal Metastases Following Cytoreductive Surgery Using Pegsitacianine, a pH-Sensitive Imaging Agent: Final Results from a Phase II Study.
Ann Surg Oncol;
2024 Apr 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38622456
4.
Serial cytoreductive surgery and survival outcomes in recurrent adult-type ovarian granulosa cell tumors.
Am J Obstet Gynecol;
230(5): 544.e1-544.e13, 2024 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38191019
5.
Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy.
Nature;
613(7945): E3, 2023 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36627494
6.
Neuroendocrine neoplasms of the ovary: a review of 63 cases.
Int J Gynecol Cancer;
34(4): 566-573, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38290783
7.
EphA2- and HDAC-Targeted Combination Therapy in Endometrial Cancer.
Int J Mol Sci;
25(2)2024 Jan 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38279277
8.
Clinical implications of tumor-based next-generation sequencing in high-grade epithelial ovarian cancer.
Cancer;
129(11): 1672-1680, 2023 06 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36930815
9.
Phase II Trial of MEDI0457 and Durvalumab for Patients With Recurrent/Metastatic Human Papillomavirus-Associated Cancers.
Oncologist;
28(7): 618-623, 2023 07 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37104874
10.
Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer.
Gynecol Oncol;
168: 76-82, 2023 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36423446
11.
Quality-adjusted survival in women with gynecologic malignancies receiving IMRT after surgery: A Ppatient Rreported Ooutcome study of NRG oncology's RTOG 1203.
Gynecol Oncol;
175: 176-181, 2023 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37393743
12.
Clinical outcomes of leuprolide acetate in the treatment of recurrent ovarian granulosa cell tumors.
Am J Obstet Gynecol;
228(6): 724.e1-724.e9, 2023 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36907533
13.
Clinical Application of Poly(ADP-Ribose) Polymerase (PARP) Inhibitors in Ovarian Cancer.
Cancer Treat Res;
186: 71-89, 2023.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37978131
14.
Low-grade serous ovarian cancer: expert consensus report on the state of the science.
Int J Gynecol Cancer;
33(9): 1331-1344, 2023 09 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37591609
15.
Combination of EphA2- and Wee1-Targeted Therapies in Endometrial Cancer.
Int J Mol Sci;
24(4)2023 Feb 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36835335
16.
Targeting the DNA damage response beyond poly(ADP-ribose) polymerase inhibitors: novel agents and rational combinations.
Curr Opin Oncol;
34(5): 559-569, 2022 09 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35787597
17.
Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survival.
Gynecol Oncol;
167(2): 139-145, 2022 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36137845
18.
Adjuvant therapy in women with early stage uterine serous carcinoma: A multi-institutional study.
Gynecol Oncol;
167(3): 452-457, 2022 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36243601
19.
The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes.
Gynecol Oncol;
165(3): 560-567, 2022 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35606067
20.
Frailty repels the knife: The impact of frailty index on surgical intervention and outcomes.
Gynecol Oncol;
166(1): 50-56, 2022 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35599168